News
Team ROTOP is back from SNMMI 2025 in New Orleans
July 18. 2025 - Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical world.
First marketing authorization for RoTecPSMA®
May 14, 2025 - We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care, making advanced diagnostics more accessible for those affected by prostate cancer.
ROTOP Pharmaka GmbH Announces Investments from GENUI & SHS Capital and New President, ROTOP USA.
January 20, 2025 - ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA. With the new investments ROTOP secured from GENUI & SHS Capital, ROTOP is further positioned to expand the footprint and be a significant player in the CDMO space to provide clinical and commercial batch volumes both in cold and hot products.
Radiopharmacy: Radiation made in Saxony
January 16, 2025 - Saxon radiopharmacy network nukliD® strengthens international visibility. Today, Thursday 16 January 2025, leading German and international players in the field of radiopharmacy from Saxony agree to intensify their collaboration. The aim of the partners from the fields of research, industry and cluster management is to develop radiopharmacy in Saxony into a centre of innovation and expertise in this pioneering field and thus make it more visible internationally. To this end, have joined forces under the name Radiopharmacy Cluster Dresden - nukliD®.
Healthcare Specialists GENUI and SHS Capital jointly invest in ROTOP
January 15, 2025 - The Healthcare Specialists GENUI and SHS Capital are jointly investing in ROTOP, a leading European manufacturer and CDMO for radiopharmaceuticals.
ROTOP Expands to Drive Innovation!
April 10, 2024 - On more than 15,000 sqm in Dresden-Rossendorf, research and production facilities for the development of radiopharmaceutical innovations will be established in the future. The focus is on contract development and manufacturing services (CDMO) for clinical trials, as well as on commercial cGMP production of radiopharmaceutical drugs in the fields of cancer diagnostics and therapy.
